Quick Answer
BridgeBio Pharma, Inc. reported Total Revenue of $502.08 million for the year ending 2025.
- BridgeBio Pharma, Inc. showed an increase of +126.3% in Total Revenue from 2024 to 2025.
- This data is from BridgeBio Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $26.74 million | Q3 2020: $8.13 million | Q1 2021: $462.0 thousand | Q2 2021: $54.02 million | Q3 2021: $2.34 million | Q1 2022: $1.69 million | Q2 2022: $73.75 million | Q3 2022: $338.0 thousand | Q1 2023: $1.83 million | Q2 2023: $1.64 million | Q3 2023: $4.09 million | Q1 2024: $211.12 million | Q2 2024: $2.17 million | Q3 2024: $2.73 million | Q1 2025: $116.63 million | Q2 2025: $110.57 million | Q3 2025: $120.70 million.
- Over the full 7 years of available data (2019 to 2025), BridgeBio Pharma, Inc.'s Total Revenue has grown by 1,137.9%.
- Historical annual values: Fiscal year 2025: $502.08 million | Fiscal year 2024: $221.90 million | Fiscal year 2023: $9.30 million | Fiscal year 2022: $77.65 million | Fiscal year 2021: $69.72 million | Fiscal year 2020: $8.25 million | Fiscal year 2019: $40.56 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: